

References

S-33

1. Driver VR, Lavery LA, Reyzelman AM, et al. A clinical trial of Integra Template for diabetic foot ulcer treatment. *Wound Repair Regen.* 2015;23(6):891-900.
2. Cazzell S, Lange D, Dickerson J, et al. The management of diabetic foot ulcers with porcine small intestine submucosa tri-layer matrix: A randomized controlled trial. *Advances In Wound Care.* 2015;4(12):711-718.
3. Austin R, Merchant N, Shahrokhi S, et al. A comparison of Biobrane™ and Cadaveric Allograft for temporizing the acute burn wound: Cost and procedural time. *Burns.* 2015;41(4):749–753.
4. Santema TB, Poyck P, Ubbink DT. Skin grafting and tissue replacement for treating foot ulcers in people with diabetes. *Cochrane Database of Systematic Reviews.* 2016;2:CD011255.
5. American Society of Plastic Surgeons. Tissue-engineered products provide new options for skin coverage. 2015.
6. National Institute for Health and Care Excellence (NICE). Diabetic foot problems: Prevention and management. 2016.
7. Lee KT, Mun GH. Updated evidence of acellular dermal matrix use for implant-based breast reconstruction: A meta-analysis. *Ann Surg Oncol.* 2016;23(2):600-610.
8. Zelen CM, Orgill DP, Serena T, et al. A prospective, randomised, controlled, multicentre clinical trial examining healing rates, safety and cost to closure of an acellular reticular allogenic human dermis versus standard of care in the treatment of chronic diabetic foot ulcers. *Int Wound J.* 2017;14:307-315.
9. Chang E, Liu J. Prospective unbiased experience with three acellular dermal matrices in breast reconstruction. *J Surg Oncol.* 2017;9999:1–6.
10. Hayes, Inc. Clinical Research Response. *DermACELL human acellular matrix for non-healing wounds.* Lansdale, PA: Hayes, Inc.; 2018.
11. Yeh D, Nazarian R, Demetri L, Mesar T et al. Histopathological assessment of OASIS Ultra on critical-sized wound healing: a pilot study. *J Cutan Pathol.* 2017;44:523–529.
12. Hayes, Inc. Hayes Medical Technology Directory Report. *Skin Substitutes for Chronic Foot Ulcers in Adults with Diabetes Mellitus: A Review of Reviews.* Lansdale, PA: Hayes, Inc; Nov. 2017.
13. Hayes, Inc. Hayes Medical Technology Directory Report. *Skin Substitutes for Chronic Venous Leg Ulcers in Adults: A Review of Reviews.* Lansdale, PA: Hayes, Inc; Nov. 2017.
14. Brown-Etris M, Milne CT, Hodde JP. An extracellular matrix graft (Oasis wound matrix) for treating full-thickness pressure ulcers: A randomized clinical trial. *J Tissue Viability.* 2019;28:21-26. Lee KT, Mun GH. Updated evidence of acellular dermal matrix use for implant-based breast reconstruction: A meta-analysis. *Ann Surg Oncol.* 2016;23(2):600-610.
15. Zelen CM, Orgill DP, Serena T, et al. A prospective, randomised, controlled, multicentre clinical trial examining healing rates, safety and cost to closure of an acellular reticular allogenic human dermis versus standard of care in the treatment of chronic diabetic foot ulcers. *Int Wound J.* 2017;14:307-315.
16. Chang E, Liu J. Prospective unbiased experience with three acellular dermal matrices in breast reconstruction. *J Surg Oncol.* 2017;9999:1–6.

17. Hayes, Inc. Clinical Research Response. *DermACELL human acellular matrix for non-healing wounds*. Lansdale, PA: Hayes, Inc.; 2018.
18. Yeh D, Nazarian R, Demetri L, Mesar T et al. Histopathological assessment of OASIS Ultra on critical-sized wound healing: a pilot study. *J Cutan Pathol*. 2017;44:523–529.
19. Hayes, Inc. Hayes Medical Technology Directory Report. *Skin Substitutes for Chronic Foot Ulcers in Adults with Diabetes Mellitus: A Review of Reviews*. Lansdale, PA: Hayes, Inc; Nov. 2017.
20. Hayes, Inc. Hayes Medical Technology Directory Report. *Skin Substitutes for Chronic Venous Leg Ulcers in Adults: A Review of Reviews*. Lansdale, PA: Hayes, Inc; Nov. 2017.
21. Brown-Etris M, Milne CT, Hodde JP. An extracellular matrix graft (Oasis wound matrix) for treating full-thickness pressure ulcers: A randomized clinical trial. *J Tissue Viability*. 2019;28:21-26.

22. Lee KT, Mun GH. Updated evidence of acellular dermal matrix use for implant-based breast reconstruction: A meta-analysis. *Ann Surg Oncol*. 2016;23(2):600-610.
23. Zelen CM, Orgill DP, Serena T, et al. A prospective, randomised, controlled, multicentre clinical trial examining healing rates, safety and cost to closure of an acellular reticular allogenic human dermis versus standard of care in the treatment of chronic diabetic foot ulcers. *Int Wound J*. 2017;14:307-315.
24. Chang E, Liu J. Prospective unbiased experience with three acellular dermal matrices in breast reconstruction. *J Surg Oncol*. 2017;9999:1–6.
25. Hayes, Inc. Clinical Research Response. *DermACELL human acellular matrix for non-healing wounds*. Lansdale, PA: Hayes, Inc.; 2018.
26. Yeh D, Nazarian R, Demetri L, Mesar T et al. Histopathological assessment of OASIS Ultra on critical-sized wound healing: a pilot study. *J Cutan Pathol*. 2017;44:523–529.
27. Hayes, Inc. Hayes Medical Technology Directory Report. *Skin Substitutes for Chronic Foot Ulcers in Adults with Diabetes Mellitus: A Review of Reviews*. Lansdale, PA: Hayes, Inc; Nov. 2017.
28. Hayes, Inc. Hayes Medical Technology Directory Report. *Skin Substitutes for Chronic Venous Leg Ulcers in Adults: A Review of Reviews*. Lansdale, PA: Hayes, Inc; Nov. 2017.
29. Brown-Etris M, Milne CT, Hodde JP. An extracellular matrix graft (Oasis wound matrix) for treating full-thickness pressure ulcers: A randomized clinical trial. *J Tissue Viability*. 2019;28:21-26.